Overview

Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Thirty-two subjects diagnosed with COPD were enrolled, received each study treatment and completed the follow-up assessments. During each of the four study periods, subjects were admitted to the clinic on Day -1 and housed overnight until after the last spirometry measurement. Serial pulmonary function tests were performed and PK (pharmacokinetics) samples collected up to 25 hours. Subjects were discharged from the clinic on Day 2 after evaluations.
Phase:
Phase 2
Details
Lead Sponsor:
Mylan Inc.
Theravance Biopharma R & D, Inc.
Collaborator:
Theravance Biopharma
Treatments:
Ipratropium